ETFs to Buy as Lockheed Shares Jump Post Q3 Earnings Beat, Record Backlog

Lockheed Martin shares rose 9.6% after Q3 2026 EPS of $7.97 beat consensus by 6.4% and revenue of $20.7B beat by 1.4%; backlog reached a record $292B, supported by a $52.5B multi-year PAC-3 interceptor award. Lockheed raised 2026 sales guidance to $80B-$82B, though the midpoint is below the $81.07B consensus, while quarterly free cash flow fell 9% year over year to $3B and capital expenditure rose 15.2%. The article highlights ETFs with 5.59%-9.54% Lockheed weightings; RBC and Citi raised price targets while maintaining their respective Sector Perform and Buy ratings.

Analysis

The key issue is conversion, not order-book size: a multi-year interceptor award can support revenue visibility while still requiring capacity, working capital and execution before it becomes free cash flow. The near-term watch is whether missile production growth outpaces capital spending and whether F-35 contract negotiations preserve cash conversion. A larger backlog alone does not resolve either risk.

The positive reaction also leaves less room for merely good execution. Guidance midpoint below the cited consensus is a reminder that backlog growth and earnings beats may not translate into further estimate revisions. Over 1–3 months, watch for updated cash-flow guidance, contract terms and production-rate evidence; over 6–18 months, delivery capacity and government funding determine whether demand becomes margin and cash or schedule pressure. Raytheon, Northrop Grumman and other defense suppliers may benefit from sector demand, but Lockheed-specific awards are not automatically their revenue.

The ETF framing overstates diversification: PPA and SHLD each have about 9.5% in Lockheed, so they retain meaningful single-name exposure alongside defense-sector risk. ITA’s lower Lockheed weight reduces that concentration but adds commercial-aerospace exposure. The contrarian risk is that investors treat a record backlog as near-term cash; the counterpoint is that a successful production ramp could drive further upward estimate revisions. This is a watch-and-selectivity setup, not a reason to chase the post-results move.

Key Decisions for Investors

• Avoid chasing LMT immediately after the sharp repricing. Reassess on a pullback or after evidence that higher production is translating into cash flow; the thesis weakens if free cash flow continues to deteriorate or guidance is cut.
• For diversified defense exposure with less LMT concentration, prefer ITA over PPA on the supplied holdings data, while recognizing that ITA introduces commercial-aerospace exposure and is not a hedge against a sector drawdown.
• Treat SHLD and PPA as concentrated defense bets, not substitutes for single-stock risk management. Verify current holdings and fund liquidity before entry; the article’s reported trading volume for DUTY is exceptionally low, so avoid assuming it is readily tradable.
• Track F-35 Lots 20+ contract/funding outcomes, missile-production ramp milestones, capital expenditure and cash conversion over the next 1–3 months. Stronger cash generation alongside delivery progress would support the bull case; funding delays, schedule slippage or weaker cash conversion would falsify it.